(Q37807159)

English

Targeted molecular therapy in melanoma

scientific article published on September 2010

In more languages

edit

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

23 August 2017

1 reference

29 December 2023

https://doi.org/10.12788/j.sder.2020.001

title

Targeted molecular therapy in melanoma (English)

1 reference

stated in

Europe PubMed Central

23 August 2017

2

Keith T Flaherty

1 reference

stated in

Europe PubMed Central

23 August 2017

Igor Puzanov

1

1 reference

stated in

Europe PubMed Central

23 August 2017

1 September 2010

1 reference

stated in

Europe PubMed Central

23 August 2017

Seminars in Cutaneous Medicine and Surgery

1 reference

stated in

Europe PubMed Central

23 August 2017

29

1 reference

stated in

Europe PubMed Central

23 August 2017

3

1 reference

stated in

Europe PubMed Central

23 August 2017

196-201

1 reference

stated in

Europe PubMed Central

23 August 2017

Mutations of the BRAF gene in human cancer

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1038/NATURE00766

Cancer statistics, 2009

1 reference

28 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.3322/CAAC.20006

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.SDER.2010.06.005

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.SDER.2010.06.005

The INK4a/ARF locus and melanoma

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.SDER.2010.06.005

BRAFE600-associated senescence-like cell cycle arrest of human naevi

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.SDER.2010.06.005

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.SDER.2010.06.005

Cancer: Melanoma troops massed.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.SDER.2010.06.005

BRAF mutations are common somatic events in melanocytic nevi.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.SDER.2010.06.005

Improving melanoma classification by integrating genetic and morphologic features

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.SDER.2010.06.005

CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.SDER.2010.06.005

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.SDER.2010.06.005

Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.SDER.2010.06.005

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.SDER.2010.06.005

Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.SDER.2010.06.005

Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.SDER.2010.06.005

Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.SDER.2010.06.005

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.SDER.2010.06.005

Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.SDER.2010.06.005

Acquired resistance to tyrosine kinase inhibitors during cancer therapy

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.SDER.2010.06.005

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.SDER.2010.06.005

Somatic activation of KIT in distinct subtypes of melanoma

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.SDER.2010.06.005

Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.SDER.2010.06.005

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.SDER.2010.06.005

Cancer research. Melanoma drug vindicates targeted approach.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.SDER.2010.06.005

Inside life of melanoma cell signaling, molecular insights, and therapeutic targets

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.SDER.2010.06.005

Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.SDER.2010.06.005

STI571: a paradigm of new agents for cancer therapeutics

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.SDER.2010.06.005

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.SDER.2010.06.005

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.SDER.2010.06.005

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.SDER.2010.06.005

Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.SDER.2010.06.005

KIT gene mutations and copy number in melanoma subtypes

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.SDER.2010.06.005

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.SDER.2010.06.005

Epidermal growth factor receptor inhibitors in non-small cell lung cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.SDER.2010.06.005

High frequency of BRAF mutations in nevi

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.SDER.2010.06.005

Is B-Raf a good therapeutic target for melanoma and other malignancies?

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.SDER.2010.06.005

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.SDER.2010.06.005

Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.SDER.2010.06.005

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.SDER.2010.06.005

Distinct sets of genetic alterations in melanoma

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.SDER.2010.06.005

Identifiers

DOI

10.1016/J.SDER.2010.06.005

1 reference

stated in

Europe PubMed Central

23 August 2017

1 reference

Europe PubMed Central

PubMed ID

21051014

retrieved

23 August 2017

(Q37807159)

Targeted molecular therapy in melanoma

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)